共 156 条
[21]
Franzen L(1988)Strontium-89 therapy: measurement of absorbed dose to skeletal metastases J Nucl Med 29 549-557
[22]
Parker C(2005)OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine J Nucl Med 46 1023-1027
[23]
Tyrrell C(2014)Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP Eur J Nucl Med Mol Imaging 41 238-252
[24]
Blom R(2007)Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation Eur J Nucl Med Mol Imaging 34 1031-1038
[25]
Tennvall J(2007)A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases Nucl Med Commun 28 623-630
[26]
Parker CC(1992)Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma J Nucl Med 33 1316-1323
[27]
Pascoe S(1998)Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP J Nucl Med 39 2110-2115
[28]
Chodacki A(1990)Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer Radiology 176 155-159
[29]
O'Sullivan JM(1991)Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo J Nucl Med 32 1877-1881
[30]
Germá JR(2003)Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases J Nucl Med 44 953-960